持续小剂量地塞米松加沙立度胺治疗难治性多发性骨髓瘤的临床疗效观察

目的:观察持续小剂量地塞米松加沙立度胺对难治性多发性骨髓瘤的疗效.方法:持续小剂量地塞米松加沙立度胺治疗难治性多发性骨髓瘤21例,治疗方法用沙立度胺初始剂量100～200 mg/d,晚上1次顿服,从100 mg开始的患者过2周后加量至200 mg,以后维持在200 mg,地塞米松给予1.5 mg,每天2次口服,二药联合小剂量应用,持续3个月,在后1个半月,地塞米松可减量至1.5 mg,每天1次.3个月后进行化疗1个疗程,3个月为1个周期.结果:2个周期治疗后有6例部分缓解,9例进步,6例无效,其中3例加重,总有效率达71.4%.结论:持续小剂量地塞米松加沙立度胺治疗难治性多发性骨髓瘤疗效确切,不良反应少.

Clinical observation of the combination of continue low-dose Dexamethasone and thalidomide for the treatment of refractory multiple myeloma

Objective:To observe the efficacy and side effect of the continue low-dose Dexamethasone and thalidomide for the treatment of refractory multiple myeloma.Method:Twenty-one patients were treated with continue low-dose Dexamethasone and thalidomide.Treatment protocol was as following:Thalidomide was administered at the dose of 100mg to 200mg at bedtime and associated with dexamethasone administered orally at the dose of 1.5 mg twice a day for three months.Dexamethasone can been reduced to 1.5 mg/d after one and half months.Three months is a cycle.some patients need chemotherapy between two cycles.Result:A fall in paraprotein levels of greater than 50% was observed in six of the 21 patients and greater than 20% was observed in nine of the 21 patients.the remaining six showed disease static or progression.Treatment effective rate was 71.4%.Conclusion:We conclude that the continue low-dose Dexamethasone and thalidomide is a feasible and active regimen in the treatment of refractory multiple myeloma without intolerable side effects.